东诚药业：加强投资者沟通传递公司声音

Core Viewpoint - Dongcheng Pharmaceutical's stock price has been declining, causing concern among investors despite recent advancements in nuclear medicine research, product approvals, and inclusion in medical insurance [1] Group 1: Company Response - The company acknowledges that stock price fluctuations are influenced by various factors including macroeconomic conditions, market sentiment, and industry changes [1] - Dongcheng Pharmaceutical commits to fulfilling its information disclosure obligations and enhancing communication with investors [1] - The company emphasizes its strategy of high-quality development, aiming to improve operational efficiency and profitability to strengthen its core competitiveness and achieve long-term value growth [1]